HIMS Investors Have the Opportunity to Lead the Hims & Hers Health Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. due to allegations of misleading statements and the termination of its partnership with Novo Nordisk, which has significantly impacted the company's stock price [3][5][6]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in Hims between April 29, 2025, and June 23, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Hims, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [3][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Hims - The complaint alleges that Hims and its executives violated federal securities laws by making false or misleading statements regarding the safety and legitimacy of their products [5]. - Specific allegations include the deceptive promotion of illegitimate versions of Wegovy® and the risk of termination of collaboration with Novo Nordisk due to these practices [5][6]. - Following the announcement of the partnership termination by Novo Nordisk, Hims' stock price fell by $22.24, or 34.6%, closing at $41.98 per share on June 23, 2025 [6]. Group 3: Call for Information - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Hims' conduct [8].